- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01893580
Perioperative Rehabilitation in Operation for Lung Cancer (PROLUCA)
Background: Improved surgical techniques combined with effective adjuvant chemotherapy, has led to a better survival in individuals with NSCLC. The treatment of NSCLC and other cancer diseases are after all still complex and potentially lethal.
Study aim: The rationale for the study PROLUCA is to identify the optimal timing of exercise to improve recovery after surgery in patients operated for lunge cancer with focus on physical capacity and quality of life.
Who can participate? Patients above 18 years and diagnosed with lung cancer and referred for operation. Participation in this study is not possible if the participants by a doctor are advised not to do strenuous exercise.
What does the study involve? The intervention consists of a combination of (1) exercise before surgery and (2) exercise after surgery for lung cancer.
- Exercise before surgery is a home-based exercise program is individually designed and must be performed for at least 30 minutes every day until surgery. The home-based exercise program varies in length due to number of days until surgery, and the intention is not exceed 14 days.
- The exercise initiated two weeks and 6 weeks after surgery consists of a 12 weeks rehabilitation program and three individual counseling sessions. Special needs in terms of smoking cessation, nutritional counseling or patient education, this is also offered. The exercise consists of individually prepared supervised strength - and fitness exercise in a team, two sessions of 60 minutes/week.
What interventions will be compared? A home-based post-operative exercise program, combined with exercise initiated two weeks after surgery, will be compared with usual care (exercise initiated six weeks after surgery).
Will all participants receive the same treatment?
By draw it is decided which of the 4 groups the participants will attend to in the study:
- Group 1: Home-based exercise before surgery and rehabilitation initiated as early as two weeks after surgery
- Group 2: Home-based exercise before surgery and rehabilitation initiated six weeks after surgery
- Group 3: Rehabilitation initiated as early as two weeks after surgery
- Group 4: Rehabilitation initiated six weeks after surgery (Usual practice as control group) What are the possible benefits and risks of participating? There are no risks or side- effects of participating other than muscle soreness and exercise is beneficial when it comes to recover from an operation from lung cancer.
Přehled studie
Postavení
Podmínky
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Nørrebro
-
Copenhagen, Nørrebro, Dánsko, DK-2200
- Copenhagen Centre for Cancer and Health
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Performance status 0-2 (WHO)
- Living in the City of Copenhagen or surrounding Municipalities
- Ability to read and understand Danish
- Approval by primary surgeon
Exclusion Criteria:
- Presence of metastatic disease or surgical inoperability
- Diagnosis of Lung Cancer not verified by histological diagnosis
- Cardiac disease
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: 1. Experimental
Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
|
Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:
Ostatní jména:
|
|
Experimentální: 2. Experimental
Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
|
Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:
Ostatní jména:
|
|
Experimentální: 3. Experimental
Exercise in a team initiated two weeks after surgery.
|
Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of: Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM.
Ostatní jména:
|
|
Jiný: 4. Usual care
Exercise in a team initiated six weeks after surgery.
|
Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too. The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Maximum oxygen uptake (VO2peak)
Časové okno: VO2peak is assessed at baseline, the day before surgery, post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
VO2peak is evaluated by an incremental test using an electromagnetically braked cycle ergometer (Lode Corival Ergometer©).
Inspired and expired gases are analyzed breath-by-breath by a metabolic cart (JAEGER MasterScreen CPX©).
Subjects begin pedaling at seven watts and resistance increases after a predefined 10 watts ramp protocol until exhaustion or a symptom-limited VO2peak is achieved (pain, dizziness, anxiety etc.).
|
VO2peak is assessed at baseline, the day before surgery, post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Six minute walk distance (6MWD)
Časové okno: baseline, the day before surgery, pre-intervention (2/6 weeks after surgery), post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
baseline, the day before surgery, pre-intervention (2/6 weeks after surgery), post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
|
|
Patient reported outcomes (PROs)
Časové okno: Baseline, the day before surgery, pre-intervention (2/6 weeks after surgery), post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
PROs will include health related quality of life, symptoms and side-effects, anxiety and depression, well-being, distress, lifestyle, sickness absence, work status, and social support.
|
Baseline, the day before surgery, pre-intervention (2/6 weeks after surgery), post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
|
Pulmonary function
Časové okno: Baseline, the day before surgery, post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
forced expiratory volume at one second
|
Baseline, the day before surgery, post-intervention (14/18 weeks after surgery), six months after surgery, and one year after surgery.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Jesper Holst Pedersen, MD, DrMSci, Department of Cardiothoracic Surgery RT
- Ředitel studie: Jette Vibe-Petersen, MD, Copenhagen Centre for Cancer and Health
- Vrchní vyšetřovatel: Maja Schick Sommer, MHS, Copenhagen Centre for Cancer and Health
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- PROLUCA
- 2007-58-0015 (Danish Data Protection Agency)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Rakovina plic
-
Argentinian Intensive Care SocietyDokončenoDechová frekvence | End-exspiratory Lung Impedance | Zlomek tloušťky membrány | Exkurze brániceArgentina
-
Indiana UniversityRichard L. Roudebush VA Medical CenterDokončeno
-
Novartis PharmaceuticalsDokončenoNeuroendokrinní nádory | Advanced NET of GI Origin | Advanced NET of Lung OriginSpojené státy, Kolumbie, Itálie, Tchaj-wan, Spojené království, Belgie, Česko, Německo, Japonsko, Saudská arábie, Kanada, Holandsko, Španělsko, Korejská republika, Libanon, Rakousko, Čína, Řecko, Jižní Afrika, Thajsko, Maďarsko, Krocan a více
-
Assiut UniversityZatím nenabírámeRakovina plic | Poranění plic | Bleb Lung
-
University Hospital, Clermont-FerrandCentral Hospital, Nancy, FranceDokončenoDítě, Pouze | Spontánní pneumotorax | Idiopatický pneumotorax | Bleb LungFrancie
-
University of LorraineDokončenoDítě, Pouze | Spontánní pneumotorax | Idiopatický pneumotorax | Bleb LungFrancie
-
Jiangsu HengRui Medicine Co., Ltd.DokončenoNon Small Cell LungČína
-
SanofiRegeneron PharmaceuticalsDokončenoKarcinom | Non Small Cell LungSpojené státy, Francie, Kanada, Německo, Holandsko, Portugalsko, Španělsko, Švédsko, Čína, Bulharsko, Estonsko, Indie, Malajsie, Singapur, Tchaj-wan, Argentina, Rakousko, Finsko, Maďarsko, Itálie, Austrálie, Chile, Hongkong, Polsko, Řecko, ... a více
-
Taichung Veterans General HospitalDokončenoKardiotoxicita | Nádor plic bez malých buněk (MeSH termín: Carcinoma, Non-Small-Cell Lung) | Lékové nežádoucí účinky a nežádoucí reakce (MeSH termín) | Inhibitor tyrozinkinázy EGFRTchaj-wan
-
EpiBiologicsNáborRakovina hlavy a krku | Nemalobuněčný karcinom plic | Spinocelulární karcinom hlavy a krku | Spinocelulární karcinom hlavy a krku | Rakoviny hlavy a krku | HNSCC | Hlava a krk | Non Small Cell | Epidermální růstový faktor | EGFR | Spinocelulární karcinom hlavy a krku HNSCC | NSCLC (nemalobuněčný karcinom plic) | Non... a další podmínkySpojené státy
Klinické studie na Experimental: 1. Experimental
-
Cardenal Herrera UniversityDokončenoHypertenze | ObezitaŠpanělsko
-
Reistone Biopharma Company LimitedDokončeno
-
University of BurgundyDokončeno
-
The Hospital for Sick ChildrenDokončeno
-
Taisy Cinthia Ferro CavalcanteNáborKardiovaskulární choroby | Polyfenoly | Autonomní nervový systémBrazílie
-
PfizerDokončeno
-
PfizerDokončeno
-
University of Sao Paulo General HospitalDokončeno
-
Orasis Pharmaceuticals Ltd.DokončenoPresbyopieSpojené státy